NASD · Healthcare · Biotechnology · USA
Bio-Techne Corp is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.
Bio-Techne develops, manufactures and sells life science reagents, instruments and services for research, diagnostics and bioprocessing markets globally. Its Protein Sciences segment provides biological reagents and protein analysis tools for researchers and pharmaceutical companies, while its Diagnostics and Spatial Biology segment offers diagnostic products, tissue-based assays and instrumentation for spatial genomics and clinical applications.
From its FY2026 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Bio-Techne Corp stock.
Overvalued: intrinsic value $23.26 per share, market price $72.49, margin of safety -211.6% (as of 2026-10-19).
Discounting its cash flows at 10.9% (average of 3 methods) values the shares at $23.26; the price of $72.49 is 212% above that value, and 69% of that value comes from beyond year five.
Leak Score: 43/100 on 12 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
74 more in this industry show a wider margin of safety.
TECH is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 10.9% (average of 3 methods) values the shares at $23.26; the price of $72.49 is 212% above that value, and 69% of that value comes from beyond year five.
$23.26 per share (as of the 2026-10-19 close), against a market price of $72.49. That is a margin of safety of -211.6%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
43 out of 100, which we rate "On Watch", on 12 of 12 value investing signals.